Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies

Cell Cycle

Volumn 9, Issue 6, 2010, Pages 1167-1181

  Joseph, Thomas Leonard ^a   Madhumalar, Arumugam ^a   Brown, Christopher John ^b   Lane, David P ^b   Verma, Chandra ^a  

^a BIOINFORMATICS INSTITUTE   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

Author keywords

MDM2; MDMX; Molecular simulations; Nutlin; p53

Indexed keywords

PIPERAZINE DERIVATIVE; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

ARTICLE; BINDING AFFINITY; ENTROPY; MOLECULAR DYNAMICS; PLASTICITY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SIMULATION;

RUMEX;

EID: 77953495954     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.6.11067     Document Type: Article

References (91)

1. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358:15-6.
2. Harris CC. p53 tumor suppressor gene: from the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis 1996; 17:1187-98.
3. El-Deiry W. Regulation of p53 downstream genes. Seminars Cancer Biol 1998; 8:345-57.
4. Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9.
5. Shimizu H, Burch LR, Smith AJ, Dornan D, Wallace M, Ball KL, et al. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem 2002; 277:28446-58.
6. Candeias MM, Malbert-Colas L, Powell DJ, Daskalogianni C, Maslon MM, Naski N, et al. p53 mRNA controls p53 activity by managing Mdm2 functions. Nat Cell Biol 2008; 10:1098-105.
7. Naski N, Gajjar M, Bourougaa K, Malbert-Colas L, Fåhraeus R, Candeias MM. The p53 mRNA-Mdm2 interaction. Cell Cycle 2009; 8:31-4.
8. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358:80-3.
9. Marchetti A, Buttitta F, Girlando S, Dalla Palma P, Pellegrini S, Fina P, et al. Mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 1995; 175:31-8.
10. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53:2736-9.
11. Blueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993; 82:2617-23.
12. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 1996; 15:5349-57.
13. Marine JC, Jochemsen AG. Mdmx as an essential regulator of p53 activity. Biochem Biophys Res Commun 2005; 331:750-60.
14. Linares LK, Hengstermann A, Ciechanover A, Müller S, Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci USA 2003; 100:12009-14.
15. Poyurovsky MV, Priest C, Kentsis A, Borden KL, Pan ZQ, Pavletich N, et al. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J 2007; 26:90-101.
16. Uldrijan S, Pannekoek WJ, Vousden KH. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J 2007; 26:102-12.
17. Bottger V, Bottger A, Garcia-Echeverria C, Ramos YF, van der Eb AJ, Jochemsen AG, et al. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 1999; 18:189-99.
18. Lee HJ, Srinivasan D, Coomber D, Lane DP, Verma CS. Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study. Cell Cycle 2007; 6:2604-11.
19. Dastidar SG, Lane DP, Verma CS. Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. J Am Chem Soc 2008; 130:13514-5.
20. Zhong H, Carlson HA. Computational studies and peptidomimetic design for the human p53-MDM2 complex. Proteins 2005; 58:222-34.
21. Grässlin A, Amoreira C, Baldridge KK, Robinson JA. Thermodynamic and Computational Studies on the Binding of p53-Derived Peptides and Peptidomimetic Inhibitors to HDM2. Chembiochem 2009; 10:1360-8.
22. Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle 2008; 7:1604-12.
23. Ramos YF, Stad R, Attema J, Peltenburg LT, van der Eb AJ, Jochemsen AG. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res 2001; 61:1839-42.
24. Hu B, Gilkes DM, Chen J. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 2007; 67:8810-7.
25. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents P53 activation by the MDM2 inhibitor nutlin. J Biol Chem 2006; 281:33030-5.
26. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444:61-6.
27. Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 2009; 7:1-11.
28. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-8.
29. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008; 105:3933-8.
30. Pazgier M, Liu M, Zou G, Yuan W, Li C, Li C, et al. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci USA 2009; 106:4665-70.
31. Harker EA, Daniels DS, Guarracino DA, Schepartz A. Beta-peptides with improved affinity for hDM2 and hDMX. Bioorg Med Chem 2009; 17:2038-46.
32. Madhumalar A, Lee HJ, Brown CJ, Lane DP, Verma CS. Design of a novel MDM2 binding peptide based on the p53 family. Cell Cycle 2009; 8:2828-36.
33. Robinson JA. Beta-hairpin peptidomimetics: design, structures and biological activities. Acc Chem Res 2008; 41:1278-88.
34. Michel J, Harker EA, Tirado-Rives J, Jorgensen WL, Schepartz A. In Silico Improvement of beta3-peptide inhibitors of p53 x hDM2 and p53 x hDMX. J Am Chem Soc 2009; 131:6356-7.
35. Sakurai K, Schubert C, Kahne D. Crystallographic analysis of an 8-mer p53 peptide analogue complexed with MDM2. J Am Chem Soc 2006; 128:11000-1.
36. Czarna A, Popowicz GM, Pecak A, Wolf S, Dubin G, Holak TA. High affinity interaction of the p53 peptideanalogue with human Mdm2 and Mdmx. Cell Cycle 2009; 8:1176-84.
37. llen J, Goepfert A, Blechschmidt A, Izaac A, Geiser M, Tavares G, et al. Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes. J Biol Chem 2009; 284:8812-21.
38. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 2006; 66:3169-76.
39. Boehr DD, Nussinov R, Wright PE. The role of dynamic conformational ensembles in biomolecular recognition. Nat Chem Biol 2009; 5:789-96.
40. Schames JR, Henchman RH, Siegel JS, Sotriffer CA, Ni H, McCammon JA. Discovery of a novel binding trench in HIV integrase. J Med Chem 2004; 47:1879-81.
41. Rutherford K, Daggett V. The V119I polymorphism in protein L-isoaspartate O-methyltransferase alters the substrate-binding interface. Protein Eng Des Sel 2009; 22:713-21.
42. Dodson GG, Lane DP, Verma CS. Molecular simulations of protein dynamics: new windows on mechanisms in biology. EMBO Rep 2008; 9:144-50.
43. Ding Y, Mei Y, Zhang JZ. Quantum mechanical studies of residue specific hydrophobic interactions in p53-MDM2 binding. J Phys Chem B 2008; 112:11396-401.
44. Espinoza-Fonseca LM, Garcia-Machorro J. Aromaticaromatic interactions in the formation of the MDM2-p53 complex. Biochem Biophys Res Commun 2008; 370:547-51.
45. Chen HF, Luo R. Binding induced folding in p53-MDM2 complex. J Am Chem Soc 2007; 129:2930-7.
46. Espinoza-Fonseca LM, Trujillo-Ferrara JG. Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations. Biopolymers 2006; 83:365-73.
47. Massova I, Kollman PA. Computational Alanine scanning to probe protein-protein interactions: A novel approach to evaluate binding free energies. J Am Chem Soc 1999; 121:8133-43.
48. Carotti A, Macchiarulo A, Giacchè N, Pellicciari R. Targeting the conformational transitions of MDM2 and MDMX: Insights into key residues affecting p53 recognition. Proteins 2005; 77:524-35.
49. Macchiarulo A, Giacchè N, Carotti A, Baroni M, Cruciani G, Pellicciari R. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition. J Chem Inf Model 2008; 48:1999-2009.
50. Popowicz GM, Czarna A, Holak TA. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 2008; 7:2441-3.
51. INK4a loss. Genes Dev 2008; 22:1337-44.
52. Li Y, Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 2007; 26:2220-5.
53. Vousden KH. Functions of p53 in metabolism and invasion. Biochem Soc Trans 2009; 37:511-7.
54. Amadei A, Linssen AB, Berendsen HJ. Essential dynamics of proteins. Proteins 1993; 4:412-25.
55. Hayward S, Kitao A, Go N. Harmonicity and anharmonicity in protein dynamics: a normal mode analysis and principal component analysis. Proteins 1995; 23:177-86.
56. Hayward S, Kitao A, Hirata F, Go N. Effect of solvent on collective motions in globular protein. J Mol Biol 1993; 234:1207-17.
57. Hayward S, Kitao A, Go N. Harmonic and anharmonic aspects in the dynamics of BPTI: a normal mode analysis and principal component analysis. Protein Sci 1994; 3:936-43.
58. Lee H, Mok KH, Muhandiram R, Park KH, Suk JE, Kim DH, et al. Local structural elements in the mostly unstructured transcriptional activation domain of human p53. J Biol Chem 2000; 275:29426-32.
59. Jagadeesh MN, Madhumalar A, Beuerman RW, Lane DP, Verma CS. Differences in the transactivation domains of p53 family members: a computational study. BMC genomics 2009; (In Press).
60. Schon O, Friedler A, Bycroft M, Freund SMV, Fersht AR. Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol 2002; 323:491-501.
61. Bottger A, Bottger V, Garcia-Echeverria C, Chene P, Hochkeppel H, Sampson W, et al. Molecular characterization of the HDM2-p53 interaction. J Mol Biol 1997; 269:744-76.
62. Fischer S, Verma CS, Hubbard RE. Rotation of structural water inside a protein: calculation of the rate and vibrational entropy of activation. J Phys Chem B 1998; 102:1797-805.
63. Fischer S, Verma CS. Binding of buried structural water increases the flexibility of proteins. Proc Natl Acad Sci USA 1999; 96:9613-5.
64. Madhumalar A, Smith DJ, Verma C. Stability of the core domain of p53: insights from computer simulations. BMC Bioinformatics 2008; 9:17.
65. Kallen J, Goepfert A, Blechschmidt A, Izaac A, Geiser M, Tavares G, et al. Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes. J Biol Chem 2009; 284:8812-21.
66. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor supressor transactivation domain. Science 1996; 274:948-53.
67. Ohtaka H, Freire E. Adaptive inhibitors of the HIV-1 protease. Prog Biophys Mol Biol 2005; 88:193-208.
68. Balius TE, Rizzo RC. Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry 2009; 48:8435-48.
69. Freedman DA, Epstein CB, Roth JC, Levine AJ. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol Med 1997; 3:248-59.
70. Mendes J, Baptista AM, Carrondo MA, Soares CM. Improved modeling of side-chains in proteins with rotamer-based methods: a flexible rotamer model. Proteins 1999 37:530-43.
71. Bower MJ, Cohen FE, Dunbrack RL Jr. Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. J Mol Biol 1997 267:1268-82.
72. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008; 105:2070-5.
73. Bartel F, Meye A, Wurl P, Kappler M, Bache M, Lautenschlager C, et al. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma Int J Cancer 2001; 95:168-75.
74. Taubert H, Kappler M, Meye A, Bartel F, Schlott T, Lautenschläger C, et al. A MboII polymorphism in exon 11 of the human MDM2 gene occuring in normal blood donors and in soft tissue sarcoma patients: an indication for an increased cancer susceptibility? Mutat Res 2000; 456:39-44.
75. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, Duke RE, et al. AMBER8. San Francisco: University of California 2004.
76. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, et al. A second-generation force field for the simulation of proteins, nucleic acids and organic molecules. J Am Chem Soc 1995; 117:5179-97.
77. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA, Development and testing of a general AMBER force field. J Comput Chem 2004; 25:1157-74.
78. Wang J, Wang W, Kollman PA, Case DA, Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model 2006; 25:247-60.
79. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983; 79:926-35.
80. Darden T, York D, Pedersen L. Particle mesh Ewald: An N.log(N) method for Ewald sums in large systems. J Chem Phys 1993; 98:10089-92.
81. van Gunsteren WF, Berendsen HJC. Algorithms for macromolecular dynamics and constraint dynamics. Mol Phys 1977; 34:1311-27.
82. Bashford D, Case DA. Generalized Born models of macromolecular solvation effects. Annu Rev Phys Chem 2000; 51:129-52.
83. Tsui V, Case DA. Molecular dynamics simulations of nucleic acids with a Generalized Born solvation model. J Am Chem Soc 2000; 122:2489-98.
84. Jayaram B, Sprous D, Beveridge DL. Solvation free energy of biomacromolecules: Parameters for a modified Generalized Born model consistent with the AMBER force field. J Phys Chem B 1998; 102:9571-6.
85. Connolly ML. Solvent-accessible surfaces of proteins and nucleic acids. Science 1983; 221:709-13.
86. Sanner MF, Olson AJ, Spehner JC. Reduced surface: An efficient way to compute molecular surfaces. Biopolymers 1996; 38:305-20.
87. Case DA. Normal-mode analysis of protein dynamics. Curr Opin Struct Biol 1994; 4:285-90.
88. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: Application to microtubules and the ribosome. Proc Natl Acad Sci USA 2001; 98:10037-41.
89. DeLano WL. The PyMOL molecular graphics system. San Carlos CA, USA: DeLano Scientific 2002.
90. Humphrey W, Dalke A, Schulten K. VMD-visual molecular dynamics. J Mol Graph 1996; 14:33-8.
91. Canutescu AA, Shelenkov AA, Dunbrack RL Jr. A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci 2003; 12:2001-14.